Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
Quantitative Imaging Workshop XX
Digestive Disease Week 2024
2024 NCCN Annual Conference
European Association of Urology Congress 2024
AACR Annual Meeting 2024
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.
Showing All Recent Newsreels Videos
Select Meeting
Toggle Dropdown
2021 ASCO Annual Meeting
AACR Annual Meeting 2021
SGO 2021 Virtual Annual Meeting on Womens Cancer
NCCN 2021 Virtual Annual Conference
Quick Chats
View all
Advertisement
2024 NCCN Annual Conference
William J. Gradishar, MD, on HR-Positive, HER2-Negative Breast Cancer: Management Update
Natalie S. Callander, MD, on Multiple Myeloma: Management Updates
Wendy Vogel, MSN, FNP, AOCNP, FAPO, on the Evolving Role of Advanced Practice Providers in Oncology Care
Douglas B. Johnson, MD, MSCI, on Cutaneous Melanoma: Treatment Updates
AACR Annual Meeting 2024
Kelly K. Hunt, MD, on Breast Cancer and Neoadjuvant Therapy: Expert Commentary
Pasi A. Jänne, MD, PhD, on NSCLC, Osimertinib, Chemotherapy: Update From FLAURA2
2024 Society of Surgical Oncology Annual Meeting
Natália Polidorio, MD, PhD, on Triple-Negative Breast Cancer: Impact of Race on Treatment Efficacy
Heather McArthur, MD, MPH, on Early-Stage High-Risk ER+/HER2− Breast Cancer: New pCR Results for Pembrolizumab and Chemotherapy
Kerollos N. Wanis, MD, PhD, on Risks for BRCA Mutation Carriers Treated With Breast-Conserving Therapy
Akhil G. Pachimatla, MD, on NSCLC: A Link Between Image-Based Measures of Obesity and Metabolic Pathways
Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer
Jenny H. Chang, MD, on New Findings on Merkel Cell Carcinoma and Neoadjuvant Immunotherapy
Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy
SGO 2024 Annual Meeting on Womens Cancer
Brian M. Slomovitz, MD, on Cervical Cancer: Update on Tisotumab Vedotin vs Chemotherapy
Mansoor R. Mirza, MD, on Endometrial Cancer: Update on Combination Regimen of Dostarlimab, Chemotherapy, and Niraparib
Mary McCormack, PhD, MBBS, on Locally Advanced Cervical Cancer: Results From the INTERLACE Trial
Anne Knisely, MD, on Ovarian Cancer and the Implications of Detecting Residual Disease and ctDNA
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy
Ana Oaknin, MD, PhD, on Recurrent Cervical Cancer: New Findings on Atezolizumab, Bevacizumab, and Chemotherapy
2024 Multidisciplinary Head and Neck Cancers Symposium
Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib
Christopher A. Barker, MD, on New Data on Vismodegib and Radiotherapy for Basal Cell Carcinoma of the Head and Neck
Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck
Pooja Karukonda, MD, on Coping With Financial Toxicity in Head and Neck Cancer
Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors
Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer
Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance
Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer
Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report
Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC
2024 ASCO GU Cancers Symposium
Neeraj Agarwal, MD, on Prostate Cancer: Phase III Trial Update on Cabozantinib, Atezolizumab, and Hormonal Therapy
Maha H.A. Hussain, MD, on Prostate Cancer: New Data on Abiraterone and Prednisone Plus Olaparib
Amanda Nizam, MD, on Urothelial Carcinoma: Study Results on Enfortumab Vedotin and Avelumab
Thomas Powles, MD, on RCC: Patient-Reported Outcomes With Belzutifan vs Everolimus
Syed Muneeb Alam, MD, on Urothelial Carcinoma: Microsatellite Instability and Response to Immune Checkpoint Blockade
Umang Swami, MD, on Prostate Cancer: Differences in Genomic, Transcriptomic, and Immune Landscape Based on Site of Metastasis
Saby George, MD, on Clear Cell Kidney Cancer: Subcutaneous vs Intravenous Nivolumab
Michiel S. Van Der Heijden, MD, PhD, on Metastatic Urothelial Carcinoma: Phase III Trial Data on Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy
Enrique Grande, MD, on Adrenocortical Carcinoma: Phase II Results on Cabozantinib Plus Atezolizumab
David H. Aggen, MD, PhD, on Advanced Bladder Cancer: HER2 and PD-L1 Immunohistochemistry and HER2 Genomic Alterations
Andrew Johns, MD, on Clear Cell Renal Cell Carcinoma: Data on Tivozanib in Pretreated Patients
Thomas Powles, MD, on Clear Cell Kidney Cancer: Overall Survival Update With Adjuvant Pembrolizumab
Rohit K. Jain, MD, MPH, on Urothelial Carcinoma: New Data on Cabozantinib Plus Pembrolizumab
Andrea B. Apolo, MD, on Urothelial Carcinoma: Phase III Findings on Pembrolizumab vs Observation
2024 ASCO GI Cancers Symposium
Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies
Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648
Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: New Data on Nivolumab, Ipilimumab, and Chemotherapy
Manish A. Shah, MD, on Esophageal Cancer: Long-Term Outcomes of Pembrolizumab and Chemotherapy
Frank Kullmann, MD, on Metastatic Pancreatic Cancer: Recent Data on Gemcitabine and Nab-Paclitaxel
Anant Ramaswamy, DM, on Advanced Gastric Cancers: New Findings on Adding Docetaxel to Doublet
Van K. Morris, MD, on Colon Cancer: ctDNA as a Predictive Biomarker
Riccardo Lencioni, MD, on Hepatocellular Carcinoma: Transarterial Chemoembolization, Durvalumab, and Bevacizumab
Jennifer Yon-Li Wo, MD, on Colorectal and Pancreatic Cancers: New Findings on SBRT With Ipilimumab and Nivolumab
Lorraine A. Chantrill, PhD, MBBS, on Gastrointestinal Neuroendocrine Carcinomas: First-Line Treatment With Nab-Paclitaxel Plus Carboplatin
Milind M. Javle, MD, on Cholangiocarcinoma: New Data on Tinengotinib as Monotherapy
Yasunobu Ishizuka, MD, on Gastric Cancer: Does Nivolumab Infusion Time of Day Matter?
Dominik P. Modest, MD, on Colorectal Cancer: Health-Related Quality-of-Life Findings From CodeBreaK 300
Ian Chau, MD, on Gastrointestinal Cancers: Real-World Effectiveness of Nivolumab Plus Chemotherapy
2023 ASH
Jonathon B. Cohen, MD, on Mantle Cell Lymphoma: New Data on Pirtobrutinib
Danai Dima, MD, on Multiple Myeloma: Update on Safety and Efficacy of Teclistamab
Bijal D. Shah, MD, on Previously Treated Mantle Cell Lymphoma: New Findings on Brexucabtagene Autoleucel and Pirtobrutinib
Pieter Sonneveld, MD, PhD, on Newly Diagnosed Multiple Myeloma: Phase III Findings on Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone
Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy
Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?
William G. Wierda, MD, PhD, on Use of Pirtobrutinib for Richter Transformation: Updated Efficacy and Safety Results
Potential Clinical Uses of Identifying New Hematologic Malignancy Predisposition Gene
Sarah C. Rutherford, MD, on Hodgkin Lymphoma: Nivolumab Plus AVD in Older Patients With Advanced-Stage Disease
Jennifer A. Woyach, MD, on CLL/SLL: 30-Month Follow-up and Subgroup Analysis of Pirtobrutinib
Michael Wang, MD, on Mantle Cell Lymphoma: New Results on Ibrutinib Plus Venetoclax
Adam S. Kittai, MD, on Richter’s Transformation: Anti-CD19 CAR T-Cell Therapy
Sara Khan, DO, on the Gender Gap in Receiving NIH Grants for Hematology Research
Sanjal H. Desai, MBBS, on Classical Hodgkin Lymphoma: Improving Outcomes With PD-1 Blockade
Andrew Srisuwananukorn, MD, on Myelofibrosis vs Essential Thrombocythemia: A Potential New Clinical Decision Tool
Jeffrey E. Rubnitz, MD, PhD, on Pediatric AML Outcomes and Racial Disparities
Mazyar Shadman, MD, MPH, on Large B-Cell Lymphoma: Autologous Transplantation vs CAR T-Cell Therapy
Harinder Gill, MD, MBBS, on Acute Promyelocytic Leukemia: Assessing the Use of Oral Arsenic Trioxide, Retinoic Acid, and Ascorbic Acid
Ibrahim Aldoss, MD, on KMT2A-Rearranged Acute Leukemia: New Data on Revumenib Monotherapy
2023 SABCS
Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine
Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen
Aditya Bardia, MD, MPH, on HR-Positive, HER2-Negative Advanced Breast Cancer: New Findings on Datopotamab Deruxtecan vs Chemotherapy
Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial
Nicholas C. Turner, MD, PhD, on High-Risk Early-Stage Breast Cancer: Profiling Primary Tumors
Senthil Damodaran, MD, PhD, on Locally Advanced or Metastatic Breast Cancer: Phase II Results on Futibatinib
Daniel G. Stover, MD, on Early-Stage Breast Cancer: A Biomarker Analysis From the PALLAS Trial
Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy
Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel
Sherene Loi, MD, PhD, on Biomarker Results in ER+, HER2– Primary Breast Cancer Following Neoadjuvant Chemotherapy With or Without Nivolumab
Barbara Pistilli, MD, on HR+, HER2– Advanced Breast Cancer: Update on Capivasertib Plus a CDK4/6 Inhibitor and Fulvestrant
Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial
Luca Gianni, MD, on Locally Advanced, HER2-Positive Breast Cancer: New Data on Neoadjuvant Therapy and Atezolizumab
Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes
Eleftherios P. Mamounas, MD, on Locoregional Irradiation, Axillary Lymph Node Involvement, and Conversion to Negative Nodes
Hope S. Rugo, MD, on Advanced Breast Cancer: Patient-Reported Outcomes From the CAPItello-291 Trial
Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib
Peter Schmid, MD, PhD, on Early-Stage TNBC: Updated Survival Results From KEYNOTE-522
Seema Khan, MD, on Ductal Carcinoma in Situ: Central MRI and a 12-Gene Expression Assay to Optimize Local Therapy
Reshma Jagsi, MD, DPhil, on Early-Stage Breast Cancer: 5-Year Outcomes With Endocrine Therapy and Breast-Conserving Surgery
Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Trial Update on Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy
24th SUO Annual Meeting
William J. Catalona, MD, on Genetic Testing in Prostate Cancer: Expert Review
Samson W. Fine, MD, on Clinical Significance of Atypical Small Acinar and Intraductal Proliferations in the Prostate
Mark D. Tyson, MD, MPH, on High-Risk Non–Muscle-Invasive Bladder Cancer: A Potential New Treatment
Stephen J. Freedland, MD, on Managing Prostate Cancer in Transgender Women
Rana R. McKay, MD, on Mutated Prostate Cancer, PARP Inhibition, and Radical Prostatectomy
Sumanta K. Pal, MD, on Prostate Cancer: Impact of the Microbiome on Immune Therapy
Bishoy M. Faltas, MD, on Upper Tract Urothelial Carcinoma: How Biology Shapes Therapy
ESMO Congress 2023
Tina Cascone, MD, PhD, on NSCLC: Phase III Results on Nivolumab, Chemotherapy, and Surgery
Jonathan D. Spicer, MD, PhD, on Early-Stage NSCLC: Survival Results With Pembrolizumab
Ze-rui Zhao, PhD, on Resectable NSCLC: SBRT With Sequential Immunochemotherapy
Hossein Borghaei, DO, on Nonsquamous NSCLC: Findings on Sitravatinib Plus Nivolumab vs Docetaxel
Mark M. Awad, MD, PhD, on NSCLC: Neoadjuvant Nivolumab Plus Ipilimumab vs Chemotherapy
Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy
Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy
Benjamin Besse, MD, PhD, on NSCLC: Safety and Efficacy Data on Novel Bispecific Antibody
Jarushka Naidoo, MHS, MBBCh, on Lung Cancer: Practice-Changing Advances Reported at ESMO 2023
IASLC 2023 WCLC
Tom E. Stinchcombe, MD, on NSCLC: Strategies for Managing Secondary Primary Disease
Ticiana A. Leal, MD, on Tumor Treating Fields and Immune Checkpoint Inhibition in Metastatic NSCLC
David H. Harpole, Jr, MD, on Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC
Chee K. Lee, PhD, MBBS, on Durvalumab, Tremelimumab, and Chemotherapy in NSCLC
Yasir Y. Elamin, MD, on Brigatinib in ALK-Rearranged Metastatic Non–Small Cell Lung Cancer
Shirish M. Gadgeel, MD, on Pembrolizumab Plus Chemotherapy for Metastatic NSCLC: 5-Year Follow-up
Seshiru Nakazawa, MD, PhD, on NSCLC and Point Mutations as de Novo Oncogenic Drivers
Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability
Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset
Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update
Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease
2023 ASCO Breakthrough Meeting
Aaron C. Tan, PhD, MBBS, on Circulating Tumor DNA: Early Biomarker of Therapeutic Response in Phase I Trials
Wei Wu, MD, PhD, on Lung Cancer: Deep Learning as a Tool for Identifying Drug-Tolerant Persister Cells
Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing
Desheng Liang, MD, PhD, on Genetic Engineering of Mesenchymal Stem Cells for Cancer Therapy
EHA Hybrid Congress 2023
Jennifer R. Brown, MD, PhD, on CLL: Resistance to Pirtobrutinib in Pretreated Disease
Matthew J. Frank, MD, PhD, on Large B-Cell Lymphoma: New Data on CD22 CAR T-Cell Therapy
Arnon Kater, MD, PhD on CLL: Recent Data on Venetoclax, Ibrutinib, and Undetectable MRD
Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel
Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin
Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease
Nikhil Munshi, MD, on Multiple Myeloma: Data From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel
Nicholas J. Short, MD, on Acute Lymphoblastic Leukemia: New Analysis of Ponatinib and Blinatumomab
Nicholas J. Short, MD on Acute Lymphoblastic Leukemia: Phase II Findings on Mini-HCVD, Inotuzumab, and Blinatumomab
2023 ASCO Annual Meeting
Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection
LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells
Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment
Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin
Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy
Eunice S. Wang, MD, and Gregory Roloff, MD, on B-ALL: Outcomes With Brexucabtagene Autoleucel in Adult Patients
Claire Roddie, PhD, MBChB, on B-ALL: Safety and Efficacy Data of Obecabtagene Autoleucel
Thomas E. Hutson, DO, PharmD, on RCC: Overall Survival Analysis of Lenvatinib, Pembrolizumab, and Sunitinib
Thierry Conroy, MD, on Rectal Cancer: Long-Term Results on mFOLFIRINOX vs Preoperative Chemoradiation Therapy
Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment
Tycel J. Phillips, MD, and Alex F. Herrera, MD, on DLBCL: New Data on ctDNA Status and Clinical Outcomes
Tycel J. Phillips, MD, and Alex F. Herrera, MD, on Classical Hodgkin Lymphoma: New Data on Nivolumab, AVD, and Brentuximab Vedotin
Guillermo Garcia-Manero, MD, on Myelodysplastic Syndromes: Luspatercept and Epoetin Alfa in Lower-Risk Disease
Narjust Florez, MD, and Roy S. Herbst, MD, on NSCLC: Overall Survival Analysis From the ADAURA Trial of Osimertinib
Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options
Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130
Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab
Bradley J. Monk, MD, on Cervical Cancer: Findings on Pembrolizumab Plus Chemotherapy
Amer Methqal Zeidan, MBBS, MHS, on Myelodysplastic Syndromes: New Data From the IMerge Study of Imetelstat
Narjust Florez, MD, and Filippo Gustavo Dall’Olio, MD, on NSCLC: New Findings on Tumor Fraction, Durvalumab, and Survival
Paula Aristizabal, MD, MAS, on Surviving Childhood Leukemia Near the Border of the United States and Mexico
Jennifer A. Ligibel, MD, on Early Breast Cancer and Weight Loss: Results From the BWEL Trial
Nagla Abdel Karim, MD, on Small Cell Lung Cancer: SWOG S1929 Results on Atezolizumab Plus Talazoparib
Tycel J. Phillips, MD, and Swetha Kambhampati, MD, on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel
Omid Hamid, MD, on Advanced Melanoma: Durable Response With Fianlimab Plus Cemiplimab
Georgina V. Long, MD, PhD, on Resected Melanoma: Biomarkers for and Efficacy of Adjuvant Nivolumab vs Placebo
Christian Pfister, MD, PhD, on Bladder Cancer: New Overall Survival Data on Perioperative Chemotherapy
Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy
Bobbie J. Rimel, MD, Isabelle L. Ray-Coquard, MD, PhD, on Cervical Squamous Carcinoma: Neoadjuvant Nivolumab Plus Ipilimumab
Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel
Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib
Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib
Allison Betof Warner, MD, PhD, and Adnan Khattak, PhD, MBBS, on High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942
Catherine C. Coombs, MD, on B-Cell Malignancies and Long-Term Safety of Pirtobrutinib
Funda Meric-Bernstam, MD, on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan
Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients
Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease
Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy
Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, on Glioma: Phase III Results on Vorasidenib
Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial
Narjust Florez, MD, and Heather A. Wakelee, MD, on Early-Stage NSCLC: Phase III Findings From KEYNOTE-671 on Pembrolizumab and Platinum-Based Chemotherapy
Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease
Jonathan W. Riess, MD, on EGFR-Mutated Non–Small Cell Lung Cancer: What’s Next?
Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716
Sarah K. Tasian, MD, on Hematologic Malignancies in Children: Expert Commentary
Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib vs Chemotherapy From the THOR Study
Penelope Bradbury, MBChB, on Pleural Mesothelioma: New Results From the IND227 Trial of Cisplatin and Pemetrexed With or Without Pembrolizumab
Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, on Localized Prostate Cancer: Prognostic Impact of PSA Nadir
Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib and Cetrelimab From the NORSE Study
Cathy Eng, MD, and Lars Henrik Jensen, MD, PhD, on Locally Advanced Colon Cancer: Efficacy of Neoadjuvant Chemotherapy and Standard Treatment
Smitha Krishnamurthi, MD, and Deb Schrag, MD, MPH, on Rectal Cancer: New Findings on Chemoradiation, Chemotherapy, and Excision
Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax
James Chih-Hsin Yang, MD, PhD, on Metastatic Nonsquamous NSCLC: Evaluating Pemetrexed and Platinum With or Without Pembrolizumab
Tycel J. Phillips, MD, and Emanuele Zucca, MD, on Primary Mediastinal B-Cell Lymphoma: New Data on Observation vs Radiotherapy
Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment
Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance
Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax
Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease
Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib
Narjust Florez, MD, and Ferdinandos Skoulidis, MD, PhD, on NSCLC: Findings on Sotorasib vs Docetaxel in the CodeBreaK 200 Trial
Reid Merryman, MD, on High-Risk Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide
Clifford A. Hudis, MD, on ASCO 2023 Perspectives: The Power of Connecting and Collaborating
Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab
Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary
Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept
Ajay K. Nooka, MBBS, on High-Risk Myeloma: Data on Carfilzomib, Pomalidomide, and Dexamethasone
Ajay K. Nooka, MBBS, Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Data for Elranatamab
Advertisement
Advertisement
May
19
Today In Oncology
Providing Culturally Sensitive Palliative Care to Children With Cancer
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer Comparison of Agents
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC
Half-Matched Family Donors May Improve ASCT Outcomes in Hispanic Patients With ALL
View More
Advertisement